CD8A and cancer: Moreover, not only the subset of T infiltrating cells but also the topographical site within the tumor seems to be a predictor of response to immunotherapy: stromal or invasive CD8+ T cells correlate with better clinical outcomes in immunotherapy-treated cancer patients [112].